| INTRODUC TI ON
Child-onset thrombotic thrombocytopenic purpura (TTP) is a rare entity of thrombotic microangiopathy (TMA), a rare and life-threatening disease, referring to pathological features of vascular damage (incidence is estimated at <1 case per million children per year).
1,2 TMA syndromes are defined by a microangiopathic hemolytic anemia (the presence of schistocytes on the blood smear), a consumption thrombocytopenia and organ damage related to disseminated thrombi in the microcirculation. 3 The pathophysiology of TTP is based on a severe functional deficiency of ADAMTS13 (A Disintegrin and Metalloprotease with ThromboSpondin type 1 repeats, member 13), the specific von
Willebrand factor-(VWF) cleaving protease. 4 Child-onset TTP may be either idiopathic or associated with miscellaneous clinical contexts (infections, autoimmune diseases, neoplasia, hematopoietic stem cells transplantation, organ graft …). Other TMA syndromes are reported in children (hemolytic uremic syndrome, HUS, associated with Shiga toxin-producing Escherichia coli enteric infection affecting predominantly the kidney and atypical HUS related to a genetic or acquired dysregulation of the complement alternative pathway 5 ) and their differential diagnosis with TTP may be challenging in children.
| PATHOPHYS IOLOGY OF THROMBOTIC THROMBOC Y TOPENIC PURPUR A
Thrombotic thrombocytopenic purpura (TTP) occurs in adulthood or less frequently in childhood (about 10% of all TTP cases). 6 Indeed, the first case of TTP was described in 1924, in a 16-year-old girl. 7 ADAMTS13 regulates the biological function of VWF-cleaving ultralarge and hyperadhesive VWF multimers. ADAMTS13-VWF interaction is crucial in the pathophysiology of TTP.
| von Willebrand factor
Von Willebrand factor (VWF) is an adhesive and multimeric glycoprotein containing several functional domains (A, C and D-domains; 
| ADAMTS13
Von Willebrand factor-cleaving protease was purified in 1996, 
| Thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura pathophysiology is specifically related to a severe functional deficiency of ADAMTS13
(ADAMTS13 activity <10% of normal). This deficiency leads to the accumulation of hyperadhesive ultralarge VWF multimers inducing the spontaneous formation of platelet-rich microthrombi within arterioles and capillaries and subsequent widespread microvascular ischemia. [18] [19] [20] TTP is characterized by a microangiopathic hemolytic anemia, a consumption thrombocytopenia, with or without multivisceral ischemia ( Figure 2) . Clinically, the acute phase of the The mechanism for ADAMTS13 severe deficiency is either inherited (~5% of all TTP cases) or acquired (~95% of all TTP cases; Figure 3 ). 2, 6, 18, 19 In children, TTP represents less than 10% of all TTP cases (~1/3 of congenital TTP and ~2/3 of acquired TTP). 
| CLINIC AL AND B I OLOG IC AL FE ATURE S OF T TP
The first case of TTP was described in 1924 by Moschcowitz. 7 A
16-year-old girl suddenly developed weakness, pain, pallor, fever, and petechiae (no platelet count available). Few days later, she developed neurological disorders (hemiparesis and paralysis), became comatose, and died. Based on the autopsy reporting the presence of disseminated hyaline thrombi in the microcirculation (heart, kidney, spleen, and liver), this patient was the first published case of TTP.
Child-onset TTP (initial episode before age 18) is very rare and represents only ~10% of all TTP cases ( Figure 3 ). In children, the first episode of TTP may be either idiopathic or associated with a clinical context (autoimmune disease, infection, hematopoietic stem cell transplantation, organ transplantation, neoplasia…). 2 In the absence of an appropriate treatment, TTP remains life-threatening.
In children, the diagnosis of TTP should be suspected when a bicytopenia (microangiopathic hemolytic anemia, and consumption thrombocytopenia) is associated with organ failure or a previous diagnosis of autoimmune cytopenia (idiopathic thrombocytopenic purpura, anemia 
Thrombotic thrombocytopenic purpura as a function of age of onset and mechanism for ADAMTS13 deficiency. Among thrombotic thrombocytopenic purpura (TTP) patients, the acquired form of the disease represents 90% of all TTP cases and the congenital form only 10%. The first episode of TTP occurred during adulthood in 95% of cases and during childhood (age < 18) in 5% of cases. Interestingly, the proportion of congenital TTP is very low in adults (2%), whereas it is as high as 35% in children [Colour figure can be viewed at wileyonlinelibrary.com] autoimmune hemolytic, or Evans syndrome) not responding to specific treatments. In the classical form of child-onset TTP, symptoms related to organ ischemia mostly concern the brain, and less frequently the heart and the kidney. TTP associates with fever, neurological features (headache, confusion, coma, seizures, strokes, or transient focal defects) and sometimes impaired renal function (proteinuria, moderate acute kidney injury). Abdominal (abdominal pain and vomiting) and cardiac features are associated to a disseminated disease.
| Acquired TTP
The prevalence of child-onset acquired TTP is ~1 case per million chil-
dren. An analysis of the literature 21 and an original study conducted in severe ADAMTS13 deficiency (ADAMTS13 activity <10%). Fever was reported in 36% of children and ischemic disorders affecting the brain, the kidney, and/or the heart were reported in 64% of cases (40%, 42%, and 7%, respectively). Impaired kidney function and acute kidney injuries were more frequent in non-idiopathic TTP (80%) than in idiopathic forms of the disease. More generally, acquired forms of child-onset TTP were mostly related to anti-ADAMTS13 autoantibodies (82%).
2
The anti-ADAMTS13 autoantibodies are mainly IgG with a neutralizing action (inhibition of the catalytic activity of ADAMTS13) and/or a nonneutralizing action (complexation of ADAMTS13 and acceleration of its clearance). The anti-ADAMTS13 antibodies are mainly directed against the spacer domain of the protease (95% of autoantibodies) ( Figure 1 ). 22 However, in some acquired TTP cases with ADAMTS13 deficiency, antibodies may be undetectable which could be related to the lack of sensitivity of available methods, 23 to anti-ADAMTS13 antibodies of IgM or IgA type, 24 to an altered synthesis or secretion of ADAMTS13, 25 to consumption or further enzymatic degradation of the protease. [26] [27] [28] The differential diagnosis between TTP and other cytopenias in children can be challenging and 31% of initial misdiagnosis (HUS, atypical HUS, autoimmune cytopenia, hematological malignancy) have been reported. 2 Consequently, the specific treatment of TTP is delayed, and organ sequelae may occur. Some patients with impaired renal function at presentation were misdiagnosed as HUS and some of them developed an end-stage renal disease in the absence of appropriate treatment. 29 The mortality rate of the acquired form of the disease is 9% in children. 2 During clinical and biological remission, anti-ADAMTS13
antibodies disappear, in parallel with the normalization of ADAMTS13 activity. The disease evolves by acute phase interspersed with remission periods, and 24% of clinical relapses were reported in the French TTP pediatric cohort. 2 Moreover, the appearance of biological features of autoimmunity (antinuclear antibodies, antidouble-stranded DNA antibodies) and/or connective tissue diseases (systemic lupus erythematosus mainly) were reported in several patients, emphasizing the recommendation of the long-term follow-up of child-onset TTP patients to rapidly diagnose these conditions and prevent tissue injury.
HLA-DRB1*11 is well established as a predisposing factor for idiopathic acquired TTP, whereas HLA-DRB1*04 is protective in Caucasian adult patients. 30 Further investigations are in progress in children.
| Congenital TTP
Congenital TTP (Upshaw-Schulman syndrome) was described by 
| D IAG NOS IS OF THROMBOTIC THROMBO C Y TOPENI C PURPUR A IN CHILDREN
ADAMTS13 is the unique biological marker able to definitely differentiate TTP from other TMA syndromes (HUS, atypical HUS) and hematological cytopenias.
| Suspicion of TMA: initial investigations
Among all TMA suspicion in children, standard biological investigations are needed to comfort the diagnosis (Table 1) . 
| ADAMTS13 investigations
ADAMTS13 is the unique sensitive and specific marker for TTP. The biological documentation of TMA syndrome requires ADAMTS13
investigations based on ADAMTS13 activity measurement in first intention. In the absence of rapid turnaround assay for ADAMTS13 activity, ADAMTS13 investigations are performed retrospectively, to document the clinical diagnosis of TMA. In other words, the result of ADAMTS13 investigations should not delay the first-line treatment of TTP when the diagnosis is highly suspected. 
| ADAMTS13 activity
ADAMTS13 activity is the most sensitive and specific parameter for TTP diagnosis. Screening for ADAMTS13 activity remains the first assay to perform when TMA is suspected. ADAMTS13 activity is measured using reference methods (FRETS-VWF73, full-length VWF ELISA), [49] [50] [51] limited to expert laboratories. Rapid turnaround assays also exist but they do not have the reliability of the reference methods. 52, 53 A severe functional deficiency in ADAMTS13 definitely confirms the diagnosis of TTP.
Moreover, long-term follow-up of pediatric TTP patients is crucial. Biological monitoring of ADAMTS13 activity of child-onset acquired TTP in remission is justified, as in adults, to prevent relapses of the disease (prognostic value of the risk of relapse).
| ADAMTS13 autoantibodies
When ADAMTS13 activity is undetectable (<10%), screening and titration of anti-ADAMTS13 autoantibodies are performed to identify the mechanism for ADAMTS13 deficiency (autoimmune, other possible mechanism). 22 In congenital TTP, some patients benefit from regular prophylactic plasmatherapy. Anti-ADAMTS13 antibodies are also screened and titrated in these patients, to identify the potential occurrence of an alloimmunization directed against ADAMTS13. However, no case of alloimmunization against ADAMTS13 after plasmatherapy has been reported yet.
| ADAMTS13 antigen
In congenital TTP, ADAMTS13 antigen levels (reference values: 700-1400 ng/mL) are measured to characterize a quantitative or qualitative deficiency in ADAMTS13. 
| Differential diagnosis
Hemolytic uremic syndrome (HUS) is the most frequent child-onset TMA syndrome. HUS is usually associated with renal impairment and includes several distinct entities. 5, 54 An infection-associated HUS caused by Shiga-toxin-producing Escherichia coli strain (STEC-HUS, serotype O157: H7, O103, 026, mainly) is the most common child-onset TMA syndrome, particularly in children under 3 years old (consisting of 80%-90% of HUS). 55 In comparison with TTP, STEC-HUS is usually associated with bloody prodromal diarrhea, a severe renal impairment and a moderate thrombocytopenia. An infectionassociated HUS caused by Streptococcus pneumoniae (pneumonia, meningitis) is also reported in 5% of child-onset HUS. An atypical HUS (consisting of 5%-10% of HUS) is caused by dysregulation of the complement alternative pathway, mutation in DGKE (diacylglycerol kinase ε), or cobalamin C deficiency. 5, 54, 56 Autoimmune cytopenias (Evans syndrome, idiopathic thrombocytopenic purpura, and autoimmune hemolytic anemia), hematological malignancies, and autoimmune diseases (lupus, antiphospholipid syndrome, …) are also differential diagnosis of TTP. 2, 34 Moreover, partial ADAMTS13 deficiency (ADAMTS13 activity between 20 and 50%) are not specific and may be associated with miscellaneous clinical contexts (autoimmune diseases, severe infections, hepatocellular insufficiency, neoplasia, or other TMA syndromes). These partial deficiencies are due to a consumption of ADAMTS13, a decrease in synthesis and/or secretion of ADAMTS13, an inhibition of ADAMTS13 by proinflammatory cytokines (interleukin 6), or a degradation of ADAMTS13 by proteolytic enzymes (elastases, thrombin).
| TRE ATMENT OF T TP
Child-onset TTP is an emergency and requires rapid diagnosis and management in intensive care unit. Several strategies, based on our knowledge on the pathophysiology of the disease, are used in TTP ( Figure 4 ). In the congenital form of TTP, prophylactic plasmatherapy is the unique therapeutic option currently available (usually 10 mL/kg) and the frequency of plasma infusions is guided by the tolerance and chronicity of the disease. Anti-ADAMTS13 IgG titration should be performed regularly in these patients to detect the potential occurrence of anti-ADAMTS13 alloantibodies.
29,32,37,38
| Immunomodulation
In acquired TTP, steroids are usually used as an adjunctive treatment to curative first-line plasmatherapy (Figures 4 and 5) . 5) . 2, 59 Rituximab is typically effective after 2 weeks following the first infusion, and therefore, it may not prevent early death; moreover, rituximab administration needs to be associated with the pursue of daily therapeutic plasma exchange. Other immunosuppressive strategies (vincristine, pulses of cyclophosphamide, ciclosporin A and splenectomy) should be considered in the more severe forms of the disease ( Figure 5 ). 
| Other therapeutics
Transfusions of red blood cell concentrates can be used in case of profound anemia, depending on clinical tolerance. Platelet concentrates should be avoided in the absence of life-threatening hemorrhagic symptomatology, because they may exacerbate the spontaneous formation of platelet-rich and VWF-rich microthrombi. 60 
| Innovating drugs
Several novel therapies based on recombinant ADAMTS13 and anti-VWF molecules (caplacizumab, N-acetylcystein) emerge in TTP ( Figure 5 ). 57 Recombinant ADAMTS13 (rADAMTS13) is scheduled to be evaluated in a phase III therapeutic trial in the pediatric congenital form of the disease (Clini-calTrials.gov NCT02216084).
Preliminary studies are encouraging and report a good tolerance and a good efficacy of the treatment (decrease in high molecular weight multimers of VWF, increase in platelets and decrease in lactate dehydrogenase). 61 Caplacizumab, a nanobody directed against the A1 domain of VWF, inhibits the interactions between platelet GPIb and VWF and has shown safety and efficacy in a phase II clinical trial devoted to adult patients. 62 The randomized, double-blind, placebocontrolled, Phase III HERCULES study of caplacizumab in adults with acquired TTP confirm that caplacizumab results in faster resolution of acquired TTP, reducing the time to platelet count response.
Caplacizumab reduces TTP-related death, recurrence of TTP and has a favorable safety profile in adults acquired TTP patients. 63 Thanks to mucolytic properties, N-acetylcystein limits the polymerization and the adhesion of VWF multimers. 64 Promising results were reported in ADAMTS13 −/− mice, in prophylaxis treatment. 64 A Phase I clinical trial is also in progress in children (ClinicalTrials.gov NCT018008521).
| LONG -TERM FOLLOW-UP OF T TP
A regular long-term follow-up of all patients is recommended.
Our use is to propose a monitoring of ADAMTS13 activity every 3 months during the first years following the initial episode of acquired TTP. Connective tissue diseases and biological features of autoimmunity may appear during follow-up (6% and 17%, respectively, in the French pediatric cohort) and should be anticipated. 
| Prevention of relapses
Thrombotic thrombocytopenic purpura (TTP) is a pathology evolving by acute phase and remission periods. The prevention of TTP relapses is therefore a major challenge. In acquired forms of TTP, the relapse rate is ~25%. 2, 21 Biological monitoring of ADAMTS13 activity is justified by the relapsing tendency of the disease (40% of clinical relapse in the current year when ADAMTS13 < 10%, and 5% of relapse when ADAMTS13 is normal), and is aimed to detect biological relapse. Preemptive treatment with rituximab may be considered in autoimmune TTP, for patients in clinical remission when ADAMTS13 activity becomes undetectable (<10%) to avoid clinical relapse. 2, 65 In the congenital form of the disease, prophylactic plasmatherapy may be considered in chronic forms associated with organ ischemia (approximately 50% of patients). The delay between two plasma infusions (usually every 3-4 weeks) depends on each specific patient, as a function of the tolerance of the disease and the occurrence of clinical events.
| Clinical and psychological follow-up
Clinical (height, weight, body mass index, and autoimmune disease) and psychological follow-up are recommended to evaluate the emergence of autoimmune disease and physical and/or psychological sequelae of the disease. 2 Long-term follow-up (medical consultation, standard biology, and ADAMTS13 activity monitoring) is highly recommended in TTP children.
| CON CLUS I ON AND PER S PEC TIVE S
Pediatric TTP is a rare entity within a rare disease and may initially 
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